news from april 4thless than 50,000 shares now available under 20 cents.looks like people liked the news from april 4th
Ventripoint Diagnostics Ltd (C-VPT) - News Release
Ventripoint to provide VMS for Oregon hospital study
2011-04-04 10:04 ET - News Release
Shares issued 79,583,062
VPT Close 2011-04-01 C$ 0.14
Dr. George Adams reports
NOTED OREGON CARDIOLOGISTS CONDUCT FIRST STUDY ON ADULTS USING VENTRIPOINT 3D HEART ANALYSIS TECHNOLOGY
VentriPoint Diagnostics Ltd., together with its wholly owned subsidiary, VentriPoint Inc., have learned that the adult congenital heart disease team at Oregon Health & Science University (OHSU) in Portland, Ore., will be using the VentriPoint medical system (VMS) with its breakthrough and patented technology to study adults with congenital heart disease. OHSU is the second United States hospital to install a VMS and the study will be conducted by Dr. David Sahn and Dr. Craig Broberg, from its adult congenital heart program.
"As an early collaborator of VentriPoint, we are excited to participate. The VMS can give us a new, clear and highly accurate picture of the right heart in 3-D -- the hidden part of the heart -- using a relatively cheap and readily available technology that has been around for decades, 2-D ultrasound," Dr. Sahn stated.
Those suffering from congenital heart disease require life-long monitoring. Prior to the VMS, the only other methods to get a readable and accurate picture of the right ventricle were to use an expensive and hard-to-access magnetic resonance imaging or a computed tomography that uses relatively high dosages of radiation.
The incidence rate of congenital heart disease in the United States is about eight per 1,000 live births with approximately one million adults and 800,000 children currently living with congenital heart disease in the U.S.
As part of a controlled deployment plan, Ventripoint has successfully installed its medical systems in Toronto, Canada; in Europe at the Rikshospitalet University Hospital in Oslo, Norway; and in the U.S. at the University of Nebraska Medical Center/Creighton University joint division of pediatric cardiology at Children's Hospital & Medical Center in Omaha, Neb., and now at the Oregon Health & Science University in Portland, Ore. Additional VMS installations are in process and will be announced as each system becomes operational. Ventripoint expects to have at least 10 of its systems installed and operational in the U.S., Europe and Canada by the end of the second calendar quarter.
"It is rewarding to work with the leading Oregon cardiologists who see the immediate need for our technology to replace and augment expensive MRI procedures," said Dr. George Adams, chief executive officer of Ventripoint, "Ventripoint is focused on cardiovascular disease and strives to deliver products that solve real world problems as identified by the Oregon Health & Science University and other centres in the U.S., Europe and Canada."
About Dr. Sahn and Dr. Broberg
Dr. Sahn is an expert in cardiac imaging in the field of pediatric and adult congenital heart disease, and his dedication in NIH peer review earned him recognition as the first Marcy Speer Outstanding Reviewer Award honouree. Dr. Sahn is a professor of pediatrics, diagnostic radiology and biomedical engineering, and director of the interdisciplinary program for cardiac imaging at Oregon Health & Science University.
Dr. Broberg is the director of the adult congenital heart program at OHSU and is a funded investigator studying congenital heart disease. He completed his cardiology fellowship training at OHSU in 2003, and joined the division of cardiology in 2005 after an additional two-year fellowship in congenital heart disease and imaging at the Royal Brompton Hospital in London.
We seek Safe Harbor.